

1 Trends in TSH, free T4, and anti-thyroid
2 peroxidase and treatment status: Canadian
3 Health Measures Survey 2012 to 2015

4 **Authors and affiliations**

5 1. Yi-Sheng Chao, MD MPH PhD*

6 Independent researcher

7 Email: chaoyisheng@post.harvard.edu

8 *Corresponding author

9

10 *Corresponding author

11

12

13 Abstract

14 Background

15 Previous studies in Canada focused on the prevalence of thyroid conditions have not
16 reported on the levels of the thyroid-stimulating hormone (TSH) and thyroid hormones. To
17 address this issue, the present study describes the trends in TSH, free T4, and anti-thyroid
18 peroxidase and their treatment status for the patients who have clinically high or low levels.

19 Methods

20 We used data from the Canadian Health Measures Survey (CHMS) cycles 3 and 4 conducted
21 between 2012 and 2015. The thyroid measures studied were TSH, free T4, and anti-thyroid
22 peroxidase. We used clinical reference ranges to identify abnormality in these measures.
23 We labelled abnormality in these measures as *treated* if relevant conditions were diagnosed
24 or a disease-specific prescription was reported. *Untreated* individuals were those with an
25 abnormality in thyroid measures without any medication use or relevant diagnoses. We
26 presented the trends of thyroid measures in mean values and ratios, compared to the values
27 first measured.

28 Results

29 The levels of TSH, free T4, and anti-peroxidase in cycle 4 were not significantly different
30 from those in cycle 3. The proportions of Canadians with clinically high levels of free T4,
31 anti-thyroid peroxidase, and TSH were 0.03 to 0.017, 0.005 to 0.005, and 0.30 to 0.43 for
32 cycles 3 to 4, respectively. The proportions of Canadians with clinically low levels of TSH
33 and free T4 were 0.02 to 0.021 and 0.18 to 0.11 for cycles 3 to 4, respectively. The change in
34 the proportions of treatment statuses varied across the thyroid measures of the Canadians
35 studied.

36 Conclusion

37 This descriptive study demonstrates the trends in TSH, free T4, and anti-thyroid
38 peroxidase; their distributions in the population; and the proportions of Canadians with
39 clinically high or low levels. We believe the information on the treatment status of those
40 with uncontrolled high levels can be used to design patient screening programs.

41 Key words

42 Canadian Health Measures Survey (CHMS), trends, thyroid hormone, thyroid-stimulating
43 hormone, treatment status

44

45 Background

46 It was estimated that in 2008 and 2009, 10.4% of Canadians aged 45 years or older
47 had thyroid conditions (unspecified).[1, 2] Not all patients present symptoms and are
48 treated.[1] However, thyroid conditions left untreated can lead to adverse cardiac
49 outcomes, such as hypertension and dyslipidemia.[1] Asymptomatic patients can be
50 identified through population screening. The screening of thyroid conditions often is done
51 by measuring the levels of blood thyroid-stimulating hormone (TSH).[1] In clinics, free
52 thyroxine (T4) and anti-thyroid peroxidase are two of the thyroid measures tested to
53 determine a differential diagnosis of hyper- or hypothyroidism.[3]

54 Certain treatment options are available for asymptomatic thyroid conditions, such as
55 levothyroxine for screen-detected hypothyroidism.[1] However, concerns have been raised
56 with respect to the population screening for thyroid conditions. First, levels of TSH may
57 fluctuate. For example, a 5-year cohort study found that abnormal levels of TSH in some
58 primary care patients returned to normal levels.[4] Second, no strong evidence exists to
59 support treatment for asymptomatic patients. A systematic review by the Canadian Task
60 Force on Preventive Health Care found a lack of statistical significance in the differences in
61 mortality, weight change, and harms between the treated and untreated screen-detected
62 thyroid patients.[1] Therefore, screening the thyroid conditions of the general public is not
63 recommended, with the exception of those individuals with previous thyroid conditions or
64 those who have received thyroid interventions.[1] Last, overdiagnosis is a concern that may
65 occur when a condition is detected that would not otherwise have been diagnosed in an
66 individual's lifetime.[5] Globally, in developed and developing countries, a trend in thyroid
67 cancer overdiagnosis is increasing.[5] For example, in the Republic of Korea, a 15-fold
68 increase occurred in the diagnosis of thyroid cancer between 1993 and 2011, even though
69 the thyroid cancer mortality rate remained similar to the 1993 level throughout the
70 period.[6] Thus, a trend of overdiagnosis of thyroid cancer in the Republic of Korea is
71 likely.[6]

72 In Canada, thyroid cancer is not targeted by cancer screening programs[7], and
73 screening for thyroid conditions is not recommended.[1] It is unclear whether the lack of
74 support for screening is the reason why studies reporting the statistics on TSH and other
75 thyroid measures are few. Currently, little information is available as to whether an
76 overdiagnosis or undertreatment of thyroid conditions is occurring. Previous studies have
77 used a trend analysis of blood pressure and environmental chemicals to demonstrate their
78 distributions in the populations and to detect significant changes in the levels of biomarkers
79 over time.[8-10] The trends in, and the treatment status of, TSH and thyroid hormones may
80 be useful for understanding how thyroid conditions are clinically managed in Canada.
81 Therefore, this descriptive study conducts a trend analysis of TSH, free T4, and anti-thyroid
82 peroxidase—using the thyroid measures available in a national survey—to detect whether
83 significant changes in their levels are occurring in Canadians, and to estimate the treatment
84 statuses of these thyroid measures.

85 Methods

86 We used data from the Canadian Health Measures Survey (CHMS) cycles 3 and 4
87 implemented in 2012 to 2013 and 2014 to 2015, respectively.[8-10] For each of these cycle,

88 more than 5,000 non-institutionalized Canadians, aged 3 to 79 years were sampled (for
89 details about inclusion and exclusion criteria, see previous publications).[11, 12] statistical
90 weights were applied to the subjects to estimate the overall distributions and levels of
91 selected measures for more than 30 million non-institutionalized Canadians.[13] Three
92 thyroid measures were available for the CHMS cycles 3 and 4: free T4 (pmol/l), anti-thyroid
93 peroxidase (U/ml), and TSH (mIU/l).[14]

94 **Abnormality identification for blood measures**

95 We assessed TSH, free T4, and anti-thyroid peroxidase for abnormality, values
96 higher or lower than upper or lower reference limits, respectively. The reference ranges for
97 TSH were 0.4 to 4.8 mIU/l for adults and 1.7 to 9.1 mIU/l for those aged 21 weeks to 20
98 years.[15] The reference ranges for free T4 were 13 to 27 pmol/l.[15] The upper limit of the
99 anti-thyroid peroxidase reference range was 35 U/ml.[16]

100 **Treatment status identification**

101 We defined the *treatment status* according to the use of medication and the chronic
102 condition diagnoses reported by participants.[17-20] We estimated the treatment status in
103 four categories: treated, probably treated, potentially treated, and untreated (see Table 1).
104 To avoid over-identification, we defined *untreated individuals* as those who had not
105 reported the use of any medications or any related chronic conditions defined by the CHMS
106 (any chronic conditions, cardiovascular disease, high blood pressure, abnormal lipid profile,
107 stroke, kidney disease, liver disease, thyroid disease, diabetes, cancer, eating disorder, or
108 chronic obstructive pulmonary disease). We regarded individuals as *treated* only if they
109 were diagnosed with thyroid disease or who were taking thyroid prescription drugs.

110 Individuals were *probably treated* if they were diagnosed with the above-mentioned
111 chronic conditions that might affect clinical measures or were taking any prescription
112 drugs. Individuals were regarded as *potentially treated* if they reported any chronic
113 conditions or were taking any prescription or over-the-counter drugs.

114 We reported *medication use* based on the Anatomical Therapeutic Chemical (ATC)
115 classification system.[9, 21] *Medication* in the CHMS data was labelled as prescription, over-
116 the-counter drugs, and health products.[9] Over-the-counter drugs and health products
117 were regarded as *non-prescription*. [9] We extracted the ATC codes that represented
118 prescription or over-the-counter drugs from the medication file of each cycle. In Table 1,
119 the first and second levels of the ATC codes that represented thyroid medications were
120 indicated as “G03.”

121 **Data analysis**

122 We conducted a trend analysis using all the variables available from the CHMS.[8, 9,
123 22] First, we summarized these variables using basic characteristics, such as maximal and
124 minimal values, and we linked the survey and bootstrap weights to them.[22] Then, we
125 identified the missing values and the values beyond the detection levels for all the
126 variables.[10] We recorded basic statistics, such as the weighted mean, and the 25th and
127 75th percentiles.[10] We introduced clinical reference ranges to identify Canadians with
128 abnormal levels of thyroid measures. We labelled four treatment statuses based on chronic
129 conditions and medication use. We used the CHMS cycles as the proxy measure for time
130 points in our trend analysis. Using ratios, we compared the distributions of TSH, free T4,

131 and anti-thyroid peroxidase in CHMS cycle 2 (2012 to 2013) to their distributions in CHMS
132 cycle 3 (2014 to 2015).[9, 10, 23] We described the trends with ratios with 95% confidence
133 intervals (CIs). The 95% CIs of the ratios in the subsequent cycles covering 1 indicated
134 insignificant changes in the levels of thyroid measures after cycle 3. We conducted the data
135 analysis with R (v3.20)[24] and RStudio (v0.98.113).[25]

136 Results

137 The population characteristics in the same period were published.[9, 10] In
138 summary, throughout the CHMS cycles 3 to 4, around 30 million Canadians were estimated
139 and almost half of them were female.[9, 10] The mean ages of the two cycles were 39.00
140 and 39.30 years.[8-10] The trends of free T4, anti-peroxidase, and TSH of cycles 3 and 4 are
141 represented in Tables 2, 3, and 4. The levels of free T4 were all within the detection limits.
142 The proportions of individuals reaching the lower detection limits were 0.39, 0.30, and less
143 than 0.0002 for anti-thyroid peroxidase in cycles 3 and 4 and TSH in cycle 3, respectively.
144 Since the lower reference range for anti-thyroid peroxidase was not defined, and the
145 proportion of TSH lower than the detection levels was small, the proportions of thyroid
146 measures lower than the detection levels did not influence the subsequent analysis. Based
147 on the ratios in cycle 4, the levels of TSH, free T4, and anti-thyroid peroxidase were not
148 significantly different from those levels in cycle 3 (ratio 95% CIs covering 1 for all).

149 Proportions of abnormality in blood measures

150 The proportions of Canadians with levels higher or lower than the reference ranges
151 differed for TSH, free T4, and anti-thyroid peroxidase. There was an increase in the
152 proportions of Canadians with high levels of anti-thyroid peroxidase and low levels of TSH.
153 There was a decrease in the proportions of Canadians with high levels of free T4 and TSH,
154 and low levels of free T4. The proportions of Canadians with clinically high levels of free T4,
155 anti-thyroid peroxidase, and TSH were 0.005 to 0.005, 0.30 to 0.43, and 0.03 to 0.017 for
156 cycles 3 to 4, respectively. The proportions of Canadians with clinically low levels of free T4
157 and TSH were 0.18 to 0.11 and 0.02 to 0.021 for cycles 3 to 4, respectively. The lower
158 reference limit for anti-thyroid peroxidase was not defined, and the proportion with
159 clinically low levels was not available.

160 Treatment status for clinically high levels

161 The four estimated treatment status varied for TSH, free T4, and anti-thyroid
162 peroxidase. Due to an insufficient number of unweighted sample sizes, the proportions of
163 Canadians being treated with high levels of free T4 were not reported in Table 2. The
164 proportions of Canadians who were untreated—based on drug use and self-reported
165 conditions—were all less than 5% of Canadians with high levels of free T4, anti-thyroid
166 peroxidase, and TSH: 0 to 0.009, 0.02 to 0.03, and 0.01 to 0.049 for cycle 3 and 4,
167 respectively.

168 The proportions of Canadians treated with high levels of TSH and anti-thyroid
169 peroxidase were 0.31 to 0.44 and 0.15 to 0.11 for cycles 3 to 4, respectively; whereas
170 sufficient sample sizes were unavailable for estimating this proportion for free T4.

171 The present study uniquely identified two treatment statuses—*probably treated* or
172 *potentially treated*. Among those with high levels of free T4, anti-thyroid peroxidase, and

173 TSH, the proportions of being probably treated were high: 0.34 to 0.92, 0.90 to 0.90, and
174 0.87 to 0.86 for cycles 3 to 4, respectively. Among Canadians with high levels of free T4,
175 anti-thyroid peroxidase, and TSH, the proportions of being probably treated were high: 1 to
176 0.99, 0.98 to 0.97, and 0.99 to 0.95 for cycles 3 to 4, respectively.

177 **Treatment status for clinically low levels**

178 The treatment status for clinically low levels of anti-thyroid peroxidase was not
179 defined. The proportions of Canadians with low levels of free T4 and TSH were 0.18 to 0.11
180 and 0.020 to 0.021 for cycles 3 to 4, respectively. The proportions of *untreated* Canadians
181 with low levels of free T4 and TSH were 0.025 to 0.007 and 0 to 0.01 for cycles 3 to 4,
182 respectively. The proportions of Canadians being *treated* who had low levels of free T4 and
183 TSH were 0.09 to 0.04 and 0.44 to 0.41 for cycles 3 to 4, respectively.

184 The proportions of Canadians being *probably treated* were high for free T4 and TSH.
185 Thus, the proportions of Canadians with low levels of free T4 and TSH being probably
186 treated were 0.89 to 0.93 and 0.87 to 0.91 for cycles 3 to 4, respectively. The proportions of
187 Canadians being *potentially treated* were almost 1 for free T4 and TSH. Thus, the
188 proportions of Canadians with low levels of free T4 and TSH being potentially treated were
189 0.97 to 0.99 and 1 to 0.99 for cycles 3 to 4, respectively.

190 **Discussion**

191 Surprisingly, based on our findings, little attention has been paid to the trends in
192 thyroid measures, their distributions in the population, and the clinically low levels of
193 thyroid measures. Building on previous studies,[26] we did not limit the scope of our study
194 to subjects with clinically high levels.

195 The levels of TSH, free T4, and anti-thyroid peroxidase were stable throughout CHMS
196 cycles 3 to 4. According to the CHMS surveys, Canadians have high proportions of abnormal
197 (high or low) levels of anti-thyroid peroxidase and free T4 (more than 11%). The
198 proportions of Canadians with abnormal levels of TSH, a screening target, were 5% or less.
199 Also, the proportions of Canadians with high levels of anti-thyroid peroxidase and low
200 levels of TSH may have increased, and the proportions of Canadians with high levels of free
201 T4 and TSH and low levels of free T4 may have decreased.

202 High proportions of Canadians with abnormal levels of TSH, free T4, and anti-thyroid
203 peroxidase were probably treated, taking any prescriptions, or diagnosed with thyroid
204 disease or other chronic conditions, which may suggest a high health care coverage for
205 Canadians with abnormal levels of TSH, free T4, and anti-thyroid peroxidase.

206 A previous study using CHMS cycle 3 data with the same population and a slightly
207 different reference range (0.55 to 4.78 mIU/l, compared to 0.4 to 4.8 mIU/l of the present
208 study) found that the proportions of Canadians with clinically high, normal, and low levels
209 of TSH in cycle 3 were 3.33%, 93.15%, and 3.52%, respectively, compared to 3.04%,
210 94.98%, and 1.98% of the present study.[27] The similarity of these estimates suggests that
211 the analysis of the present study is accurate.

212 Since Canada lacks a comprehensive reporting of thyroid conditions, the prevalence
213 of thyroid conditions in Canada is based on sporadic reports. Between 2008 and 2009, the
214 prevalence of thyroid conditions in the Canadian population was 10.4% among those aged
215 45 years and over.[2] The estimated prevalence of thyroid condition was 5.67% and 6.85%

216 among Canadians aged 3 and over in 2009 to 2011 and 2012 to 2013, respectively.[27] In
217 the US, the prevalence of thyroid conditions was estimated to be 16.18% in women and
218 3.06% in men, reported by participants interviewed between 1999 and 2006.[28] This
219 study and others have shown that some of the patients with abnormal levels of TSH remain
220 undiagnosed.[28, 29]

221 **Treatment and clinically abnormal levels**

222 One feature of the present study is its four treatment statuses indicating the intensity
223 of medical interventions that Canadians have received. Moreover, the proportions of the
224 four treatment statuses that identified TSH, free T4, and anti-thyroid peroxidase were
225 different. The first finding based on treatment statuses is that thyroid medications are
226 rarely used by Canadians with high levels of free T4. An increase in the levels of free T4 has
227 been linked to increased risks of developing any solid cancer, lung cancer, and breast
228 cancer, regardless of the TSH levels.[30] This outcome may be due to the activation of
229 ontogenetic pathways and tumor-growth-related genes.[30] The second finding is that the
230 majority of Canadians with abnormal levels of TSH, free T4, or anti-thyroid peroxidase were
231 probably treated (were taking prescriptions or diagnosed with chronic conditions), more
232 than 86%, except free T4 in cycle 3 (34%). Whether this is due to an increase in the
233 treatment coverage, changes to clinical practice, or differences in sampling methods needs
234 to be confirmed with future CHMS cycles.

235 The third finding based on treatment statuses is that although individuals may be
236 treated, the levels of thyroid measures remain abnormal, i.e., inadequately controlled. The
237 proportions of individuals with inadequately controlled levels of lipid profile in the general
238 public have been used to assess the performance of health care systems.[18] TSH, free T4,
239 and total T3 are important measures to follow-up with patients who have a thyroid
240 condition.[31, 32] Our estimates of the proportions of uncontrolled high or low levels of
241 TSH are more than 31% or 40% among those with high or low levels of TSH, respectively.
242 The proportions of uncontrolled high or low levels of free T4 are less than 1% or more than
243 4% among those with high or low levels of free T4, respectively. We did not find similar
244 statistics reported by other researchers. Whether these present study statistics are useful
245 for assessing the efficacy of thyroid condition intervention remains to be investigated.

246 The fourth finding based on treatment statuses is that the association of medical
247 interventions with the proportions of clinically high or low levels of TSH, free T4, and anti-
248 thyroid peroxidase varies. Various factors can modify treatment efficacy, such as
249 intervention duration, treatment doses, frequency,[33], and compliance to medical
250 interventions.[20, 34, 35] It remains unclear whether the proportions of inadequately
251 controlled abnormality of thyroid measures is a useful indicator for assessing intervention
252 adequacy for those patients with abnormal levels of TSH, free T4, or anti-thyroid
253 peroxidase.

254 Last, opportunities may exist to intervene based on the association of treatment
255 statuses and abnormality in blood measures. The differences in the proportions of *being*
256 *treated* and *potentially treated* among Canadians with clinically high or low levels are more
257 than 50% for TSH, free T4, and anti-thyroid peroxidase in cycles 3 and 4. The difference
258 between being probably treated and potentially treated is taking over-the-counter
259 medications, which suggests that most Canadians with abnormal levels of TSH, free T4, or
260 anti-thyroid peroxidase were taking some medication. With respect to TSH, this suggests

261 that more than 94% of Canadians with clinically high or low levels may be targeted for
262 interventions through their regular access to medication. Several pharmacist-led initiatives
263 have been designed to screen conditions for treatment, for example, sexually transmitted
264 infections,[36] sleep apnea,[37] asthma, obesity, and hypertension.[38] Also, pediatric
265 patients have been identified by pharmacist-led screening programs.[38] Our results may
266 help to refine the directions and magnitudes that health authorities can use to design
267 population screening programs when necessary.

268 **Overdiagnosis of thyroid conditions?**

269 Korean researchers used a 15-fold increase in thyroid cancer diagnosis prevalence
270 and stable thyroid cancer mortality to demonstrate the possible extent of overdiagnosis of
271 thyroid cancer.[6] The present study was not designed to directly assess an overdiagnosis
272 or undertreatment of a thyroid condition, but the trends in, and the treatment statuses of,
273 thyroid measures can be used as the foundation for assessing these issues. Thus, the
274 present study findings can be informative for planning an investigation of the overdiagnosis
275 or undertreatment of thyroid conditions. First, it may not be adequate to assess the trends
276 in thyroid treatment solely based on the use of a thyroid prescription (ATC codes beginning
277 with G03) because the use rate is low among those with abnormal levels of TSH. Second, the
278 levels of TSH, free T4, and anti-thyroid peroxidase remain similar throughout the CHMS
279 cycles 3 and 4. These trends provide important baseline data for future monitoring.
280 Whether the trends in TSH, free T4, and anti-thyroid peroxidase may be changed or altered
281 by other factors can be studied with such data.

282 Last, the assessment of overdiagnosis is difficult with information based only on
283 blood measures and treatment status at two time points. A long-term follow-up and major
284 health outcomes, such as mortality, will be needed for assessing an overdiagnosis.[6] At the
285 same time, the measures of the CHMS are subject to changes in medical practices and
286 sampling frames, or to measurement errors.[8] Without obvious signs in CHMS cycles 3 and
287 4, this issue needs to be monitored in the future.

288 **Sick population versus sick individuals**

289 The results of the present study show that large proportions of Canadians with
290 clinically high or low levels of anti-thyroid peroxidase and free T4 may highlight the
291 shortcomings of current health care that focus more on sick individuals than the signs of
292 increasing risks to thyroid health in the general population.[39] Previous Canadian studies
293 have reported on only the proportions of patients with clinically high or low levels of
294 TSH.[27] With respect to the Canadian population, the distributions of TSH, free T4, and
295 anti-thyroid peroxidase have not been well studied, let alone the trends of their
296 distributions. Our research group has been developing tools to analyze trends in national
297 surveys[8-10] and to demonstrate the importance of trends in blood measures and
298 environmental chemicals.[8-10] If the increasing risks of thyroid conditions are limited only
299 to certain subgroups, preventive strategies should monitor and focus on individuals with
300 such characteristics, i.e., the high-risk strategies described by Geoffrey Rose.[39] However,
301 the increase in risks applies to the general population. This strategy will require policies
302 that do not focus on certain individuals, i.e., the population strategies described by Geoffrey
303 Rose.[39] We think the results of this trend analysis provide a good foundation for a

304 discussion on how to reduce the risk for Canadians to develop long-term consequences of
305 untreated or undertreated thyroid conditions.

306 **Limitations**

307 Fluctuations of large magnitudes in other blood measures or environmental
308 chemicals have occurred throughout CHMS cycles 1 to 4.[8] Besides the changes in the
309 distributions of blood measures across time, other factors may lead to different levels of
310 blood measures or various proportions of treatment statuses over time, such as differences
311 in sampling frames, quantification methods, or precisions; and changes in detection
312 levels.[8] Moreover, a lack of overall significant trends in population levels may not mean a
313 lack of significant changes in blood measure levels among subpopulations. The CHMS data
314 are not designed to track or follow-up with individuals with specific characteristics or
315 smaller geographic areas[11-13], and so it may not be adequate to conclude that significant
316 trends in all subpopulations are lacking.

317 **Conclusion**

318 Based on our findings, little attention has been paid to trends in TSH, free T4, and
319 anti-thyroid peroxidase; their distributions in the population; and clinically low levels of
320 these measures. Based on the ratios from cycles 3 to 4, significant changes are lacking in the
321 levels of TSH, free T4, and anti-thyroid peroxidase. There are more than 30% and 11% of
322 Canadians with clinically high or low levels (undetected or uncontrolled by medication) of
323 anti-thyroid peroxidase and free T4, respectively. The proportions of the four treatment
324 statuses, which represent the different treatment intensities that patients may have
325 received, are different for TSH, free T4, and anti-thyroid peroxidase. Our results show that
326 the large proportions of Canadians with clinically high or low levels of TSH, free T4, or anti-
327 thyroid peroxidase may highlight the shortcomings of current health care that focus more
328 on sick individuals than the signs of increasing risks to the thyroid health of the general
329 population. We plan to research strategies to screen undiagnosed patients, and the
330 potential causes of the high proportions of uncontrolled thyroid measures.

331 **Declaration**

332 **Required statement for the analysis of Statistics Canada data at the Research Data 333 Centre**

334 The analysis presented in this paper was conducted at the Quebec Interuniversity
335 Centre for Social Statistics, which is part of the Canadian Research Data Centre Network
336 (CRDCN). The services and activities provided by the QICSS were made possible by the
337 financial or in-kind support of the Social Sciences and Humanities Research Council
338 (SSHRC), the Canadian Institutes of Health Research (CIHR), the Canada Foundation for
339 Innovation (CFI), Statistics Canada, the Fonds de recherche du Québec - Société et culture
340 (FRQSC), the Fonds de recherche du Québec - Santé (FRQS) and the Quebec universities.
341 The views expressed in this paper are those of the authors, and not necessarily those of the
342 CRDCN or its partners[40].

343 **Ethics review**

344 The CHMS was approved by the Statistics Canada ethics committee. The informed
345 consent was obtained from all participants or, if participants are under 18, from a parent
346 and/or legal guardian.[11, 12] This secondary data analysis was approved by the ethics
347 review committee at the Centre Hospitalier de l'Université de Montréal.

348 **Acknowledgements**

349 Not applicable.

350 **Funding**

351 No specific funding was received for this project.

352 **Conflict of interests**

353 YSC is employed by the Canadian Agency for Drugs and Technologies in Health. YSC
354 conducted this study as an independent researcher out of academic curiosity without
355 external support.

356 **Author contribution**

357 YSC conceptualized and designed this study, managed and analyzed data, and
358 drafted the manuscript.

359 **Data Availability**

360 The CHMS data are not publicly available. It is against the Statistics Act of Canada to
361 release the CHMS data. The collection of the CHMS data has been approved by the ethics
362 committee within the governments of Canada. The CHMS data have been de-identified and
363 maintained by Statistics Canada. The data can be accessed through the Research Data
364 Centres administered by Statistics Canada. The details and eligibility in obtaining data
365 access can be found online (<https://www.statcan.gc.ca/eng/rdc/process>).

366 **Regulations**

367 All methods were carried out in accordance with relevant guidelines and regulations.

368

369 References

- 370
- 371 1. Birtwhistle, R., et al., *Recommendation on screening adults for asymptomatic thyroid*
372 *dysfunction in primary care*. CMAJ, 2019. **191**(46): p. E1274-E1280.
 - 373 2. Statistics Canada, *Table: 13-10-0466-01 (formerly CANSIM 105-1200)*. 2020, Statistics
374 Canada: Ottawa, ON.
 - 375 3. Sabatine, M.S., *Pocket Medicine: The Massachusetts General Hospital Handbook of*
376 *Internal Medicine*. 6 ed. Pocket Notebook Series. 2017: Wolters Kluwer Health.
 - 377 4. Meyerovitch, J., et al., *Serum Thyrotropin Measurements in the Community: Five-Year*
378 *Follow-up in a Large Network of Primary Care Physicians*. Archives of Internal
379 Medicine, 2007. **167**(14): p. 1533-1538.
 - 380 5. Li, M., L. Dal Maso, and S. Vaccarella, *Global trends in thyroid cancer incidence and the*
381 *impact of overdiagnosis*. The Lancet Diabetes & Endocrinology, 2020. **8**(6): p. 468-
382 470.
 - 383 6. Ahn, H.S., H.J. Kim, and H.G. Welch, *Korea's Thyroid-Cancer "Epidemic" — Screening*
384 *and Overdiagnosis*. New England Journal of Medicine, 2014. **371**(19): p. 1765-1767.
 - 385 7. Statistics Canada, *Cancer Screening, 2017*. 2018, Statistics Canada: Ottawa, ON.
 - 386 8. Chao, Y.-S., et al., *Opportunities and challenges from leading trends in a biomonitoring*
387 *project: Canadian Health Measures Survey 2007 to 2017*. Frontiers in Public Health,
388 2020. **8**: p. 460.
 - 389 9. Chao, Y.-S., et al., *Drug trends among non-institutionalized Canadians and the impact*
390 *of data collection changes in the Canadian Health Measures Survey 2007 to 2015*. PloS
391 one, 2019. **14**(4): p. e0214718-e0214718.
 - 392 10. Chao, Y.-S., et al., *Trend analysis for national surveys: Application to all variables from*
393 *the Canadian Health Measures Survey cycle 1 to 4*. PLOS ONE, 2018. **13**(8): p.
394 e0200127.
 - 395 11. Tremblay, M.S. and S. Connor Gorber, *Canadian health measures survey: brief*
396 *overview*. Can J Public Health, 2007. **98**(6): p. 453-6.
 - 397 12. Giroux, S., *Canadian Health Measures Survey: sampling strategy overview*. Health
398 reports / Statistics Canada, Canadian Centre for Health Information = Rapports sur
399 la sante / Statistique Canada, Centre canadien d'information sur la sante, 2007. **18**
400 **Suppl**: p. 31-36.
 - 401 13. Haines, D.A., et al., *An overview of human biomonitoring of environmental chemicals in*
402 *the Canadian Health Measures Survey: 2007-2019*. International Journal of Hygiene
403 and Environmental Health, 2017. **220**(2, Part A): p. 13-28.
 - 404 14. Statistics Canada, *Canadian Health Measures Survey (CHMS) Content summary for*
405 *cycles 1 to 8* Statistics Canada, Editor. 2015, Statistics Canada,: Ottawa, ON.
 - 406 15. Royal College of Physicians and Surgeons of Canada, *Clinical laboratory tests -*
407 *Reference values, C.l.t.-R. values*, Editor., Royal College of Physicians and Surgeons of
408 Canada,: Ottawa, ON.
 - 409 16. Longo, D., et al., *Harrison's Principles of Internal Medicine, 18th Edition*. 2011:
410 McGraw-Hill Education.
 - 411 17. Padwal, R.S., et al., *Epidemiology of Hypertension in Canada: An Update*. Canadian
412 Journal of Cardiology, 2016. **32**(5): p. 687-694.

- 413 18. Joffres, M., et al., *Dyslipidemia prevalence, treatment, control, and awareness in the*
414 *Canadian Health Measures Survey*. Can J Public Health, 2013. **104**(3): p. e252-7.
- 415 19. McAlister, F.A., et al., *Changes in the rates of awareness, treatment and control of*
416 *hypertension in Canada over the past two decades*. Cmaj, 2011. **183**(9): p. 1007-13.
- 417 20. Cutler, J.A., et al., *Trends in hypertension prevalence, awareness, treatment, and*
418 *control rates in United States adults between 1988–1994 and 1999–2004*.
419 *Hypertension*, 2008. **52**(5): p. 818-827.
- 420 21. World Health Organization, *Anatomical Therapeutic Chemical (ATC) Classification*
421 *System*. 2013. 2013.
- 422 22. Chao, Y.-S., et al., *Trend analysis for national surveys: application to all variables from*
423 *the Canadian Health Measures Survey cycle 1 to 4*. PLoS ONE, 2018. **(accepted)**.
- 424 23. Lumley, T. and M.T. Lumley, *The survey package*. hospital, 2007. **24**: p. 1.
- 425 24. R Development Core Team, *R: A language and environment for statistical computing*.
426 2016, R Foundation for Statistical Computing: Vienna, Austria.
- 427 25. RStudio Team, *RStudio: Integrated Development for R*. 2016, RStudio, Inc.: Boston,
428 MA.
- 429 26. Williams, I., et al., *Aetiology of hyperthyroidism in Canada and Wales*. Journal of
430 *Epidemiology & Community Health*, 1983. **37**(3): p. 245-248.
- 431 27. Barberio, A.M., et al., *Fluoride exposure and indicators of thyroid functioning in the*
432 *Canadian population: implications for community water fluoridation*. J Epidemiol
433 *Community Health*, 2017. **71**(10): p. 1019-1025.
- 434 28. Melzer, D., et al., *Association between Serum Perfluorooctanoic Acid (PFOA) and*
435 *Thyroid Disease in the U.S. National Health and Nutrition Examination Survey*.
436 *Environmental Health Perspectives*, 2010. **118**(5): p. 686-692.
- 437 29. Vanderpump, M.P.J., *The epidemiology of thyroid disease*. British medical bulletin,
438 2011. **99**(1).
- 439 30. Khan, S.R., et al., *Thyroid function and cancer risk: the Rotterdam study*. The Journal of
440 *Clinical Endocrinology & Metabolism*, 2016. **101**(12): p. 5030-5036.
- 441 31. Harada, T., et al., *Follow-up evaluation of thyroid function after thyroidectomy for*
442 *thyrotoxicosis*. World Journal of Surgery, 1984. **8**(4): p. 436-443.
- 443 32. Ross, D.S., et al., *2016 American Thyroid Association guidelines for diagnosis and*
444 *management of hyperthyroidism and other causes of thyrotoxicosis*. Thyroid, 2016.
445 **26**(10): p. 1343-1421.
- 446 33. Chao, Y.S., et al., *The importance of dose, frequency and duration of vitamin d*
447 *supplementation for plasma 25-hydroxyvitamin d*. Nutrients, 2013. **5**(10): p. 4067-78.
- 448 34. Ostchega, Y., et al., *Trends in Hypertension Prevalence, Awareness, Treatment, and*
449 *Control in Older U.S. Adults: Data from the National Health and Nutrition Examination*
450 *Survey 1988 to 2004*. Journal of the American Geriatrics Society, 2007. **55**(7): p.
451 1056-1065.
- 452 35. Gu, D., et al., *Prevalence, Awareness, Treatment, and Control of Hypertension in China*.
453 *Hypertension*, 2002. **40**(6): p. 920.
- 454 36. Wood, H. and S. Gudka, *Pharmacist-led screening in sexually transmitted infections:*
455 *current perspectives*. Integrated pharmacy research & practice, 2018. **7**: p. 67.
- 456 37. Perraudin, C., *The effectiveness of a community pharmacist-led intervention to*
457 *improve screening for sleep apnea in primary care—A cohort study*. Sleep Medicine,
458 2013. **14**: p. e230.

- 459 38. Elliott, J.P., et al., *Pharmacist-led screening program for an inner-city pediatric*
460 *population*. Journal of the American Pharmacists Association, 2015. **55**(4): p. 413-
461 418.
- 462 39. Rose, G., *Sick individuals and sick populations*. International Journal of Epidemiology,
463 2001. **30**(3): p. 427-432.
- 464 40. The Quebec Inter-University Centre for Social Statistics (CIQSS). *Statistics Canada*
465 *Data*. 2017 [cited 2017 Feb 1]; Available from: [https://www.ciqss.org/en/statistics-](https://www.ciqss.org/en/statistics-canada-data)
466 [canada-data](https://www.ciqss.org/en/statistics-canada-data).
467
468
469
470

471 **Table 1. The conditions and medications used to define the treatment status of TSH, free T4, and anti-thyroid**
472 **peroxidase in the Canadian Health Measures Survey, cycles 3 to 4 implemented in 2012 to 2013 and 2014 to 2015,**
473 **respectively.**

Disease categories	CHMS variables	CHMS concept	Medication	ATC codes	CHMS variables	CHMS concepts	Units
Thyroid condition	ccc_82	Has a thyroid condition	Thyroid	First and second level: G03	lab_ft4	Free thyroxine	pmol/l
					lab_tsh	Thyroid stimulating hormone (TSH) or thyrotropin	pmol/l
					lab_tpo	Anti-thyroid peroxidase	IU/ml

474 ATC = Anatomical Therapeutic Chemical; CHMS = Canadian Health Measures Survey; TSH =
475 thyroid stimulating hormone. There are five levels in the ATC classification. The first level is
476 represented by the first character of the codes. The second levels are the two digits
477 following the first character.

478
479
480
481

482 **Table 2. Trends in the Levels of Free T4 (thyroxine, pmol/l) and the Treatment Statuses in the Canadian Health**
 483 **Measures Survey Cycles 3 and 4.**

	Cycle 3 (2012 to 2013)	Cycle 4 (2014 to 2015)	Change in percentage points from Cycle 3 to 4 Mean (95% CIs, when available)
Relative changes (cycle 1 or first cycle = 1)	1 (1 to 1)	1.05 (0.94 to 1.16)	
Weighted mean	14.7 (14.35 to 15.05)	15.31 (14.92 to 15.7)	
Proportions with values lower than detection levels (%)	0	0	
Proportions with values higher than detection levels (%)	0	0	
Weighted mean	14.7 (14.35 to 15.05)	15.31 (14.92 to 15.7)	
Clinically high (%)	0.55	0.45	-0.1
Untreated among clinically high (%)	0 (0 to 0)	0.94 (-1.12 to 3)	
Untreated (%)	0 (0 to 0)	0 (0 to 0)	0
Treated among clinically high (%)	Insufficient sample sizes	Insufficient sample sizes	
Treated (%)	Insufficient sample sizes	Insufficient sample sizes	
Probably treated among clinically high (%)	33.93 (-1.9 to 69.76)	91.78 (80.61 to 102.95)	
Probably treated (%)	0.19 (-0.01 to 0.39)	0.41 (0.35 to 0.47)	0.22
Potentially treated among clinically high (%)	100 (100 to 100)	99.06 (97 to 101.12)	
Potentially treated (%)	0.55 (0.55 to 0.55)	0.45 (0.45 to 0.45)	-0.1
Clinically low (%)	17.75	11	-6.75
Untreated among clinically low (%)	2.52 (-2.42 to 7.46)	0.74 (0.21 to 1.27)	
Untreated (%)	0.45 (-0.43 to 1.33)	0.08 (0.02 to 0.14)	-0.27
Treated among clinically low (%)	8.83 (1.07 to 16.59)	4.17 (1.86 to 6.48)	
Treated (%)	1.57 (0.2 to 2.94)	0.46 (0.21 to 0.71)	-1.11
Probably treated among clinically low (%)	88.83 (85.05 to 92.61)	92.97 (90.54 to 95.4)	
Probably treated (%)	15.77 (15.1 to 16.44)	10.22 (9.95 to 10.49)	-5.55
Potentially treated among clinically low (%)	97.48 (95.66 to 99.3)	99.26 (98.73 to 99.79)	
Potentially treated (%)	17.31 (16.98 to 17.64)	10.92 (10.86 to 10.98)	-6.39

484 CI = confidence interval.

485

486

487

488

489 **Table 3. Trends in the Levels of Anti-thyroid Peroxidase (U/ml) and the Treatment Statuses in the Canadian**
 490 **Health Measures Survey Cycles 3 and 4.**

	Cycle 3 (2012 to 2013)	Cycle 4 (2014 to 2015)	Change in percentage points from Cycle 3 to 4
	Mean (95% CIs, when available)		
Relative changes (cycle 1 or first cycle = 1)	1 (1 to 1)	1.13 (0.68 to 1.58)	
Weighted mean	155.03 (114.72 to 195.34)	170.53 (120.61 to 220.46)	
Proportions with values lower than detection levels (%)	38.62	29.69	
Proportions with values higher than detection levels (%)	0	0	
Weighted mean	155.03 (114.72 to 195.34)	170.53 (120.61 to 220.46)	
Clinically high (%)	30.16	43.22	13.06
Untreated among clinically high (%)	2.05 (0.74 to 3.36)	3.15 (1.33 to 4.97)	
Untreated (%)	0.62 (0.23 to 1.01)	1.36 (0.58 to 2.14)	0.74
Treated among clinically high (%)	14.53 (9.77 to 19.29)	11.41 (9.04 to 13.78)	
Treated (%)	4.38 (2.95 to 5.81)	4.93 (3.91 to 5.95)	0.55
Probably treated among clinically high (%)	90.34 (88.48 to 92.2)	89.81 (87.85 to 91.77)	
Probably treated (%)	27.25 (26.68 to 27.82)	38.82 (37.98 to 39.66)	11.57
Potentially treated among clinically high (%)	97.95 (96.64 to 99.26)	96.85 (95.03 to 98.67)	
Potentially treated (%)	29.55 (29.16 to 29.94)	41.86 (41.08 to 42.64)	12.31
Clinically low (%)			
Untreated among clinically low (%)	Not defined	Not defined	
Untreated (%)	Not defined	Not defined	
Treated among clinically low (%)	Not defined	Not defined	
Treated (%)	Not defined	Not defined	
Probably treated among clinically low (%)	Not defined	Not defined	
Probably treated (%)	Not defined	Not defined	
Potentially treated among clinically low (%)	Not defined	Not defined	
Potentially treated (%)	Not defined	Not defined	

491 CI = confidence interval.

492

493

494
495

Table 4. Trends in the Levels of Thyroid Stimulating Hormone (mIU/l) and the Treatment Statuses in the Canadian Health Measures Survey Cycles 3 and 4.

	Cycle 3 (2012 to 2013)	Cycle 4 (2014 to 2015)	Change in percentage points from Cycle 3 to 4 Mean (95% CIs, when available)
Relative changes (cycle 1 or first cycle = 1)	1 (1 to 1)	0.57 (0.11 to 1.03)	
Weighted mean	3.27 (0.81 to 5.74)	1.88 (1.66 to 2.1)	
Proportions with values lower than detection levels (%)	0.02	0	
Proportions with values higher than detection levels (%)	0	0	
Weighted mean	3.27 (0.81 to 5.74)	1.88 (1.66 to 2.1)	
Clinically high (%)	3.04	1.69	-1.35
Untreated among clinically high (%)	1.28 (-1.52 to 4.08)	4.89 (-1.26 to 11.04)	
Untreated (%)	0.04 (-0.04 to 0.12)	0.08 (-0.02 to 0.18)	0.04
Treated among clinically high (%)	31.19 (15.1 to 47.28)	44.07 (25.1 to 63.04)	
Treated (%)	0.95 (0.46 to 1.44)	0.74 (0.43 to 1.05)	-0.21
Probably treated among clinically high (%)	86.61 (78.99 to 94.23)	86.12 (76.26 to 95.98)	
Probably treated (%)	2.63 (2.39 to 2.87)	1.46 (1.3 to 1.62)	-1.17
Potentially treated among clinically high (%)	98.72 (95.92 to 101.52)	95.11 (88.96 to 101.26)	
Potentially treated (%)	3 (2.92 to 3.08)	1.61 (1.51 to 1.71)	-1.39
Clinically low (%)	1.98	2.1	0.12
Untreated among clinically low (%)	0 (0 to 0)	1.02 (-0.98 to 3.02)	
Untreated (%)	0 (0 to 0)	0.02 (-0.02 to 0.06)	0.02
Treated among clinically low (%)	43.89 (16.69 to 71.09)	40.64 (26.49 to 54.79)	
Treated (%)	0.87 (0.32 to 1.42)	0.85 (0.56 to 1.14)	-0.02
Probably treated among clinically low (%)	87.2 (68.27 to 106.13)	90.64 (76.63 to 104.65)	
Probably treated (%)	1.73 (1.36 to 2.1)	1.9 (1.61 to 2.19)	0.17
Potentially treated among clinically low (%)	100 (100 to 100)	98.98 (97.49 to 100.47)	
Potentially treated (%)	1.98 (1.98 to 1.98)	2.08 (2.04 to 2.12)	0.1

496 CI = confidence interval.

497
498
499
500
501
502
503